Olema Pharmaceuticals Inc, abbreviated as OLMA, is a preclinical-stage biopharmaceutical company recognized as a pioneer in the development of innovative therapeutic solutions for cancer patients. The company operates with a mission to develop and commercialize therapies that inhibit hormone receptor signaling. Drawing upon emerging scientific knowledge and precision therapeutics technologies, Olema Pharmaceuticals works tirelessly to transform the future of oncology.
The company, headquartered in San Francisco, California, made its foundation on Harris Bernstein’s and Pamela Munster’s pioneering work on mechanisms of hormone receptor signaling. At the heart of Olema’s product engine is OP-1250—the company's foremost drug candidate, which prevents estrogen receptor ("ER") signaling in cancer cells. OP-1250 is a complete ER antagonist that has been seen to prevent ER activation in both primary and secondary sites, hindering the growth of ER-positive breast cancer cells.
OLMA’s innovative approach towards oncology therapeutics has positioned the company as a potential leader in the industry. The company employs a team of leading industry experts who are keen on pushing the boundaries of scientific research and medical advancement in the quest for techniques to maximize the effectiveness of patient treatment and improve their outcomes.
Olema's pipeline is robust and extends beyond its premier product, OP-1250. Other candidates under development belong to multiple different classes of drugs, each targeted at different receptors to offer a broad spectrum of therapeutic options for patients.
Olema Pharmaceuticals conducted its Initial Public Offering (IPO) on November 19, 2020, and is now publicly traded on the NASDAQ under the ticker symbol OLMA. The success of the IPO speaks volumes to the confidence investors have in the potential of the company's drug pipeline and its ability to revolutionize the field of breast cancer therapeutics.
In conclusion, Olema Pharmaceuticals has positioned itself as a dynamic and innovative player in the biotechnology sector. Its continued exploration in breakthrough therapeutics reflects its commitment to improving patient outcomes and providing novel treatment options to the global oncology market. With a promising research pipeline and a dedicated team of professionals, OLMA is poised to produce disruptive advances in the field of hormone receptor signaling cancer therapies.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Olema Pharmaceuticals (OLMA) shares rose 7.4% during mid-day trading but with significantly lower volume than average. The clinical-stage biotech recently missed quarterly EPS estimates and has a consensus "Moderate Buy" rating from analysts, with an average price target of $40.60, well above its current price. Insider selling and institutional investor activity also saw recent movements in the company's stock.
Olema Pharmaceuticals (NASDAQ:OLMA) has a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $40.60. Despite recent reductions in price targets by several brokerages, most analysts maintain buy or overweight ratings. The company's shares opened at $7.02, near a 12-month low, and it recently reported a quarterly loss exceeding consensus estimates.
Bank of America Corp DE has acquired a new stake of 334,875 shares, valued at approximately $4.19 million, in Olema Pharmaceuticals Inc. during the second quarter of 2026. This investment makes Bank of America Corp DE an owner of 0.38% of Olema Pharmaceuticals, a clinical-stage biopharmaceutical company. Despite a recent quarterly loss of $0.61 per share and a significant drop from its 52-week high, institutional investors collectively own 91.78% of OLMA, and analysts maintain a "Moderate Buy" rating with an average price target of $40.60.
Olema Pharmaceuticals (NASDAQ:OLMA) experienced a 7.1% drop in shares, trading at $8.95 with significantly reduced volume. Despite several analyst price target cuts, the stock maintains a "Moderate Buy" consensus with an average target of $40.60. The decline follows the company missing its latest quarterly earnings estimate, reporting a loss of $0.61 per share against an expected $0.55 loss.